…help our organization tackle melanoma on all fronts: research, patient and caregiver services, and advocacy. Thank you for your generous support. We cannot do what we…
…help our organization tackle melanoma on all fronts: research, patient and caregiver services, and advocacy. Thank you for your generous support. We cannot do what we…
Arizona
…Shaheen, MD Banner MD Anderson Cancer Center 2946 E Banner Gateway Dr. Gilbert, AZ 85234 480-256-6444 Bannerhealth.com Mark Gimbel, MD,…
Sylvester Comprehensive Cancer Ctr. | May 22
…Services Sylvester Comprehensive Cancer Center https://youtu.be/meTXBZcCE4Y 10:00 AM EST Side Effects of Treatment Jeanelle King Physician Assistant Melanoma and Cutaneous Oncology…
What Does It Mean To Be A Caregiver?
…person with melanoma. While it may not be a role you expected to take, it is a critical role in…
Matching / Workplace Gifts
…for the following information about AIM: AIM at Melanoma 3040 Cutting Blvd Richmond, CA 94804 EIN: 56-2427805 If your employer needs…
Video Library
Patient Education Video Library Welcome to AIM’s melanoma video library. Our extensive collection is organized, below, by subject matter in…
Melanoma Memorials
Remembering Those We Lost For those who have lost a loved one, we provide a virtual place of remembrance honoring…
Georgia
…228 Riverstone Dr. Canton, GA 30114 770-496-9400 www.gacancer.com Navneet Dhillon, MD Emory University Melanoma and Pigmented Lesion Clinic 1365 Clifton…
Washington
…Hall, MD Sylvia Lee, MD Scott Tykodi, MD, PhD Joshua Veatch, MD Virginia Mason 1100 Ninth Ave. Seattle, WA 98101…
Research
We Have a Bold Vision Our vision is to end melanoma in our lifetime. It’s big. It’s bold. And the…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026